

23 NOVEMBER 2021

LGP SECURES FIRST REGISTRATION FOR LOCALLY PRODUCED CANNABIS MEDICINE IN DENMARK

ASX ANNOUNCEMENT

Highlights:

- 🌿 LGP Denmark granted registration for its “Billinol LGP” 16% THC cannabis flower medicine in Denmark
- 🌿 Billinol LGP will be the first locally produced cannabis medicine granted registration in Denmark, with LGP only the second supplier to have a registered flower medicine in country
- 🌿 The registration is aligned with Group strategy of being first to market in key territories, including Australia, France and Poland
- 🌿 The registration also gives LGP access advantages to Nordic markets under mutual recognition scheme

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce it has been granted a product registration for its 16% THC “Billinol LGP” cannabis flower medicine by the Danish Medicines Agency.

The grant represents the culmination of a 2.5-year application process, with Billinol LGP being the first locally produced cannabis medicine in Denmark to receive product registration.

Billinol LGP will be cultivated and produced at LGP’s Denmark Facility, with the Group expecting to distribute its first products to patients before the end of the calendar year. Currently, Bedrocan is the only other medicinal cannabis manufacturer supplying cannabis flower into Denmark, with no other cannabis-based medicines available other than Sativex, Epidiolex and compounded formulations.





The registration aligns with LGP’s highly successful strategy of being first to market in key territories, enabling it to rapidly build a brand reputation for quality products and service with new market participants. LGP has successfully employed this strategy previously in Australia and France and expects to repeat it in Poland and now Denmark in the future. Under its registration, LGP is entitled to promote Billinol LGP in Denmark in the same manner as other registered medicines.

Billinol LGP will be sold in 5-gram alubag pouches. Based on current publicly available data, cannabis flower medicines typically retail in Denmark for between DKK140 – 160 (A\$29 - \$32) per gram, compared to A\$13 - \$22 per gram in Australia.

The registration also gives the Group significant access to the 27 million people living in the Nordic region. Under mutual recognition agreements with Sweden, Norway and Finland, as well as through direct prescription by Danish prescribers, patients prescribed medicinal cannabis from these countries can access registered Danish cannabis medicines supplied by Danish distributors.

ENDS

BY ORDER OF THE BOARD

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon
Chief Executive Officer
Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050



personal use only



About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis and psychedelics business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 20 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum. The Company is also licensed to supply psilocybin and is presently expanding its WA production facilities to produce psilocybin medicines.

Little Green Pharma cannabis products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

